Japanese Dose-Response Study of Rimonabant in Obese Patients
Launched by SANOFI · Apr 10, 2007
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Body Mass Index ≥25 kg/m²
- • Viceral Fat Area ≥ 100 cm²
- • Diet therapy for more than 8 weeks before start of the placebo observation period
- • Stable weight (variation \< ±3kg within 8 weeks before start of observation period)
- • At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDL-choresterol), Hypertension
About Sanofi
Sanofi is a global healthcare leader dedicated to empowering life through innovation in pharmaceuticals and vaccines. With a strong commitment to research and development, Sanofi focuses on addressing complex health challenges across various therapeutic areas, including diabetes, oncology, immunology, and rare diseases. The company leverages advanced science and technology to develop transformative therapies that improve patient outcomes. Through collaborative partnerships and a patient-centric approach, Sanofi strives to enhance global health and deliver sustainable solutions that meet the evolving needs of healthcare systems and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Trial Officials
Kohji SHIRAI, Professor
Principal Investigator
Toho University Sakura Medical Center, Japan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials